Sun Pharma extends gains post September quarter earnings; up 6% in two days

The management said the strong revenue and margins were driven by market share gain in India, sustained ramp-up of the company's global specialty business and growth in Emerging Markets

Shares of Sun Pharmaceutical Industries hit a multi-year high of Rs 1,048.25 as they rallied 3 per cent on the BSE in Tuesday's intra-day trade after the drug maker recorded double-digit topline growth, and strong margins in the September quarter (Q2FY23).

In the past two trading days, the stock has gained 6 per cent. It was trading at its highest level since April 2015. The market price of the company is heading towards at its all-time high level of Rs 1,201, which it had touched on April 7, 2015.

In Q2, Sun Pharma reported 13.1 per cent year-on-year